Europe has just given the green light to the hipra vaccine: the first injection against covid-19 designed, tested and produced in Spain. After several years of clinical studies by the pharmaceutical company and months of exhaustive analysis by the health authorities, the European Medicines Agency (EMA) has announced the final approval of the Spanish formula. The injection will be sold throughout Europe as booster dose against coronavirus that three years ago triggered the global health crisis of covid-19 and that, today, continues to cause infections throughout the world. Its use is recommended for youAny person over 16 years of age who has previously been vaccinated with Pfizer or Moderna.
The decision, issued this Thursday by the committee for medicines for human use of the European authority, arrives several months late compared to official forecasts but, finally, it arrives. After the verdict of the health authorities, the Hipra vaccine becomes the eighth immunization against covid-19 available in Europe. The European Commission approved the purchase of up to 250 million doses of this Spanish drug against the coronavirus. Spain, for its part, Spain has insured at least 3.2 million doses of this immunization produced in Amer (Girona).
Hipra’s injection will go on the market under the name ‘Bimervax’ and is presented as a “new generation vaccine” that “responds to the current needs of the pandemic,” according to Elia Torroella, executive vice president and director of R&D. and company records. The Spanish vaccine can be marketed from this very week in all the countries of the European Union that have participated in its purchase and that claim their respective vials. At the moment, there are already fourteen countries that have shown interest in having this medicine.
scientific career
Related news
The approval of Hipra’s vaccine against covid-19 is a milestone for Spanish science. “It is a source of pride to know that we are one of the seven countries capable of developing a vaccine against covid-19. Getting an immunization in three years still a record time“, highlighted Diana Morant, Minister of Science, in an interview with EL PERIÓDICO. “Beyond this vaccine against covid-19, we are now a more resilient country and better preparing for health crises that could arise in the future,” added the minister.
In the process of clinical trials, Hipra’s vaccine has shown high effectiveness rates versus all variants detected to date. Its use as a booster dose in people who have previously been vaccinated with other formulas generates “a strong and long-lasting immune response“. This, as explained by Carmen Cámara, from the Spanish Immunology Society, is due to the fact that “by changing the type of vaccine we are stimulating another type of immune cells and thus also we managed to generate a more powerful production of neutralizing antibodies“.